Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue: +268.4%
EPS: +73.8%
Free cash flow: +81.1%
Total debt: +0.27%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

114.36 5.60 +5.15%

Follow INSM

Alert me

Market cap: $23.9B
P/E: 0.0×
Fwd P/E: −64.6×
Dividend yield: —
F-score: 4/9
Altman Z: 9.29
Beneish M: −1.90
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Insmed, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Oct 29, 2026 · accepted 7:00 AM ET · Document on sec.gov · Filing index

Red flags

Short cash runway Oct 29, 2026
Insmed, Inc.’s cash and short-term investments cover about 3.4 quarters of its operating cash burn

10-Q filed Oct 29, 2026 · The filing · sec.gov
Receivables outpacing revenue Oct 29, 2026
Receivables grew 297.3% while revenue grew 268.4% year over year

10-Q filed Oct 29, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Oct 30, 2025: 21 added · 94 removed · 48 modified; 11 with only figures updated

Insmed, Inc. 10-Q filed Oct 29, 2026

Red flags

What changed

Stockrow Weekly